Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma-ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC)

Our plain-English summary of Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma-ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC), by K. Flöthmann, N. Zinne, P. Braubach, et al (Journal of Thoracic Disease, 2026).

The study

• Authors: K. Flöthmann, N. Zinne, P. Braubach, A. Meininger, I. Becker, N. Ernst, A. Ruhparwar, H. Merhej, P. Zardo
• Journal: Journal of Thoracic Disease
• Published: 2026;18(5):516
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel approach for intrathoracic drug delivery. The aim of this study was to investigate cisplatin penetration characteristics and to evaluate procedural parameters influencing drug penetration, including temperature, drug concentration and pleural barrier function, in an ex vivo model. In addition, PITAC was compared with hyperthermic intrathoracic chemotherapy (HITOC), a treatment modality applied in selected specialized centers as part of multimodal treatment concepts for MPM.

Methods: We investigated the penetration depth and intensity of aerosolized cisplatin generated using a high-pressure nebulizer in an ex vivo setting. Potential influencing factors, including temperature, cisplatin concentration and barrier function of the pleura, were gradually modified, as we sought to evaluate optimal procedural conditions. Finally, PITAC was compared with a previously standardized HITOC approach.

Results: A temperature of 42 ℃, a cisplatin concentration of 1 mg/mL, and prior removal of the pleura, improved the penetration depth and intensity of the chemotherapeutic agent. Under clinically relevant experimental conditions, aerosolized cisplatin application demonstrated greater tissue penetration compared to HITOC.

Conclusions: Our preclinical data suggest that PITAC may be a viable alternative to HITOC and warrants further clinical investigation.

© AME Publishing Company.

In plain English

This laboratory study used pig tissue, not patients, to test ways of delivering the cancer drug cisplatin into the chest for malignant pleural mesothelioma. The authors sprayed cisplatin as a pressurized aerosol (PITAC) onto post-mortem pieces of pig rib muscle lined with pleura. They compared this with bathing tissue in heated cisplatin liquid (HITOC). They changed one condition at a time: temperature, drug strength, and whether the pleura was kept or removed. Penetration was scored by staining for cisplatin damage to DNA. Penetration was greater at 42 degrees than at 20 degrees, greater at 1 mg/mL than at lower strengths, and greater after the pleura was removed. HITOC at 0.125 mg/mL, described as the highest strength usable in patients, stained an average of 0.9 muscle layers. Aerosol at 1 mg/mL stained an average of 4.0. The authors concluded that PITAC may be a viable alternative to HITOC. They stated that the model lacks blood flow, breathing and other body conditions, so the findings cannot be directly applied to patient outcomes.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Ex vivo laboratory experiment on animal tissue, comparing aerosolized cisplatin (PITAC) with heated cisplatin liquid (HITOC) and varying one treatment condition at a time
• Who was studied: Samples of pig intercostal (rib) muscle with parietal pleura. They came from domestic pigs aged 10 to 15 weeks that had been euthanized in a separate research project. Samples were collected 30 minutes after death at Hannover Medical School, Germany. The methods state ten samples per experiment. No dates are given.
• Exposure: Cisplatin, delivered either as a pressurized aerosol (PITAC) or as a heated circulating liquid (HITOC). Temperatures were 20, 36 and 42 degrees C. Concentrations were 0.25, 0.5 and 1 mg/mL for aerosol, and 0.125 and 1 mg/mL for HITOC. The pleura was either left intact or removed. Standard conditions were 42 degrees C, 1 mg/mL, aerosol, with intact pleura. The study did not examine asbestos exposure.
• Main results:
  • Aerosol at 1 mg/mL with intact pleura, at 20 degrees C: mean staining scores were 1.5 in the pleura and 1.4 in connective tissue, with no staining in muscle.
  • Aerosol at 1 mg/mL with intact pleura, at 42 degrees C: a mean of 1.0 muscle layers were stained, with an intensity score of 0.4.
  • Aerosol at 42 degrees C with pleura removed: at 0.25 mg/mL, the mean connective tissue score was 1.9, with 1.0 muscle layer stained. At 1.0 mg/mL, the connective tissue score was 2.5, with 4.0 muscle layers stained and an intensity score of 1.6.
  • For both aerosol and HITOC, removing the pleura gave greater penetration depth and higher staining intensity. HITOC with pleura removed stained a mean of 5.6 muscle layers, with an intensity score of 1.9.
  • HITOC at 1 mg/mL gave a connective tissue score of 2.9, with 4.6 muscle layers stained and an intensity score of 1.3. The authors note that this concentration cannot be used in clinical HITOC.
  • HITOC at the clinically feasible 0.125 mg/mL gave a mean connective tissue score of 1.4, with 0.9 muscle layers stained and an intensity score of 0.4.
• The authors' conclusion: The authors concluded that PITAC is technically feasible and showed favourable penetration compared with HITOC in this ex vivo model. They said PITAC may be a viable alternative to HITOC. They stated that whether this translates into better clinical outcomes requires further investigation.
• Limitations the authors state:
  • Body conditions such as blood circulation, lymph drainage, breathing movement and negative chest pressure were absent from the model.
  • Aerosol behaviour in a static experimental box may differ from how the aerosol spreads in a patient's chest.
  • Only cisplatin was evaluated.
  • The penetration findings cannot be directly extrapolated to clinical outcomes.
  • The experimental container was not meant to reproduce a patient's pleural surface area.

Topics

Medical terms in this study, explained in our Lexicon: Intrathoracic, Chemotherapy, Pleural Mesothelioma, Prognosis, Cisplatin, Pleura.

Related studies

• Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery for Pleural Malignancies-A Retrospective, Multicentre Study — M. Ried, J. Kovács, et al. (2021)
• Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy — M. Alyami, F. Mercier, et al. (2021)
• Comparison of video-assisted pleurectomy/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study — M. Migliore, M. Fiore, et al. (2023)
• Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study — M. Nowacki, M. Alyami, et al. (2018)
• Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma — U. Giger-Pabst, C. Demtröder, et al. (2018)
• Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) — K. Odendahl, W. Solass, et al. (2015)

Browse more research in Journal of Thoracic Disease, or return to medical research.